COVID-19 vaccination in France
 | This article needs additional citations for verification. (January 2023) |
 | |
| Date | 27 December 2020 – present |
|---|---|
| Location | France |
| Cause | COVID-19 pandemic in France |
| Target | Full immunisation of people in France against COVID-19 |
| Participants | 53,895,155 people have received at least one vaccine dose 52,581,073 people have been fully vaccinated |
| Outcome | 80.3% of the French population have received at least one vaccine dose 78.3% of the French population have been fully vaccinated |
| Website | solidarites-sante |
COVID-19 vaccination in France started on 27 December 2020 after the approval of Pfizer–BioNTech COVID-19 vaccine by the European Union commission.
According to a June 2022 study published in The Lancet, COVID-19 vaccination in France prevented an additional 631,000 deaths from December 8, 2020, to December 8, 2021.[1][2]
Vaccines on order
[edit]There are several COVID-19 vaccines at various stages of development around the world.
| Vaccine | Approval | Deployment |
|---|---|---|
| Pfizer–BioNTech |  21 December 2020
|
27 December 2020
|
| Moderna | 6 January 2021
|
12 January 2021
|
| Oxford–AstraZeneca | 29 January 2021
|
6 February 2021
|
| Janssen | 11 March 2021
|
23 April 2021
|
| Novavax | 20 December 2021
|
 Not yet
|
| Valneva | Pending | Not yet
|
| Sanofi–GSK | Pending | Not yet
|
| CureVac |  Request withdrawn
|
No
|
Vaccines in trial stage
[edit]| Vaccine | Type (technology) | Phase I | Phase II | Phase III |
|---|---|---|---|---|
| VLA2001 | Inactivated | Completed
|
Completed
|
In progress |
| CoVepiT | Subunit | In progress | Not yet
|
Not yet
|
| TMV-083 | Viral vector |
Vaccination strategy
[edit]The vaccination strategy put in place by the government has three principal objectives:[3]
- Reduce mortality and severe forms of the disease
- Protect caregivers and the healthcare system
- Ensure vaccine and immunization safety
The vaccine is planned to be distributed in five phases.
Phase 1
[edit]
The first phase of vaccination concerns the highest-priority audiences. Since 27 December 2020, it initially concerned nursing home and ESMS residents and staff over the age of 50. Vaccination has been open to caregivers over 50 since 2 January 2021, then to firefighters and domestic caregivers over 50 since 5 January 2021.
Phase 2
[edit]
This phase concerns people at high risk. From 18 January 2021, people aged 75 and over who do not reside in ESMS or nursing homes can be vaccinated. This phase will last until the end of February and concerns 5 million people. From the end of February, the vaccination will be open to people aged 65 to 74.
Phase 3
[edit]This phase concerns people who are more vulnerable than the general population. It will take place in the spring and include the following people.
- People aged 50 to 64.
- Precarious people and the staff accompanying them.
- People living in closed places or in collective accommodation.
- People with co-morbidities (COPD, hypertension, coronary heart disease, renal failure, cancers less than 3 years old or in progress, Trisomy 21, type I and II diabetes, obesity, people who have received organ or cell transplants strains).
- People working in an essential sector and in contact with the public (education, security, food.).
Photo taken on 2 May 2021
Phase 4 and 5
[edit]Phases 4 and 5 will allow vaccination to be widely opened to those over 18.
Progress to date
[edit]Daily updates were provided by Santé Publique France.[5]
 | Graphs are unavailable due to technical issues. There is more info on Phabricator and on MediaWiki.org. |
| Graphs are unavailable due to technical issues. There is more info on Phabricator and on MediaWiki.org. |
Vaccine deliveries
[edit]The following table details the weekly number of authorized vaccines delivered to France since the start of the crisis.[6] Among the suppliers, AstraZeneca is by far the most late compared to its initial commitments. In the 1st quarter of 2021, AstraZeneca is expected to deliver 30 million doses to the European Union, while the initial forecast was 120 million.[7][8]
| Graphs are unavailable due to technical issues. There is more info on Phabricator and on MediaWiki.org. |
| Graphs are unavailable due to technical issues. There is more info on Phabricator and on MediaWiki.org. |
See also
[edit]References
[edit]- ^ Watson, Oliver J; Barnsley, Gregory; Toor, Jaspreet; Hogan, Alexandra B; Winskill, Peter; Ghani, Azra C (23 June 2022). "Global impact of the first year of COVID-19 vaccination: a mathematical modelling study". The Lancet Infectious Diseases. 22 (9): 1293–1302. doi:10.1016/s1473-3099(22)00320-6. ISSN 1473-3099. PMC 9225255. PMID 35753318. Archived from the original on 29 June 2022. Retrieved 27 June 2022.
- ^ "COVID-19 vaccines saved nearly 20 million lives in a year, study says". CBS News. 24 June 2022. Archived from the original on 29 June 2022. Retrieved 27 June 2022.
- ^ "La stratégie vaccinale" (Press release). Ministère des Solidarités et de la Santé. 4 December 2020. Archived from the original on 29 January 2021. Retrieved 30 January 2021.
- ^ "Covid-19 : vaccination élargie à Porticcio et Bastia". France Bleu (in French). Radio France. 13 March 2021. Archived from the original on 1 May 2021. Retrieved 30 April 2021.
- ^ "Données relatives aux personnes vaccinées contre la Covid-19" (Press release). Santé publique France. Archived from the original on 29 January 2021. Retrieved 30 January 2021.
- ^ "Données relatives aux livraisons de vaccins contre la COVID-19" (Press release). Santé publique France. Archived from the original on 26 March 2021. Retrieved 29 March 2021.
- ^ "Covid-19 : AstraZeneca annonce de nouveaux retards de livraison de son vaccin à l'Union européenne". franceinfo (in French). France Télévisions. 13 March 2021. Archived from the original on 30 March 2021. Retrieved 29 March 2021.
- ^ "AstraZeneca: retards, effets secondaires... Pourquoi le vaccin anti-Covid crée la polémique de toutes parts". Le Figaro (in French). 14 March 2021. Archived from the original on 30 March 2021. Retrieved 29 March 2021.